Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

In Partnership With:

Partner | Oncology Network Providers | <b>Florida Cancer Specialists</b>

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Martin Dietrich, MD, PhD, physician, Florida Cancer Specialists and Research Institute, assistant professor of internal medicine, University of Central Florida, discusses optimizing treatment options for patients with mantle cell lymphoma (MCL).

MCL has evolved into a complex disease, requiring both community and academic oncologists to present a patient with all their treatment options, Dietrich says. Moreover, the involvement of an academic center is vital for transplant and CAR T-cell therapy to optimize treatment, Dietrich adds. Although CAR T-cell therapy is not yet broadly available, it is an option worth discussing, Dietrich continues.

The opportunity to enroll in clinical trials and utilize innovative cell-based therapies that should be reviewed in a multidisciplinary setting, Dietrich explains. Patients with MCL continue to face a high-risk disease, and using a multidisciplinary approach is key for optimizing outcomes and simplifying the experience for patients, Dietrich concludes.